APC anti-human CD326 (EpCAM) Antibody
- 产品名称：
- APC anti-human CD326 (EpCAM) Antibody
- 产品类别：
- 抗体
- 产品编号：
- 324207
- 产品应用：
- 324207
[价格]
| 规格 |
价格 |
库存 |
| 25tests |
￥ 1788 |
1 |
- Verified Reactivity
- Human
- Antibody Type
- Monoclonal
- Host Species
- Mouse
- Immunogen
- DU.4475 breast carcinoma
- Formulation
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
- Preparation
- The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
- Concentration
- Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
- Application
-
FC - Quality tested
- Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood.
- Excitation Laser
- Red Laser (633 nm)
- Application Notes
Additional reported applications (for the revelant formats) include: immunofluorescence,?immunohistochemistry3, and spatial biology (IBEX)4,5.
- Application References
(PubMed link indicates BioLegend citation) -
- Lammers R, et al. 2002. Exp. Hematol. 30:537.
- Schultz LD, et al. 2010. P. Natl. Acad. Sci. USA 107:13022. PubMed
- Human Protein Atlas http://www.proteinatlas.org/ENSG00000119888/antibody (IHC)
- Radtke AJ,?et al. 2020.?Proc Natl Acad Sci USA. 117:33455-33465. (SB)?PubMed
- Radtke AJ,?et al. 2022.?Nat Protoc. 17:378-401. (SB)?PubMed
- Product Citations
-
- Mulay A, et al. 2021. Cell Reports. 35(5):109055. PubMed
- Tang C, et al. 2020. Stem Cell Research. 39:101511.. PubMed
- Yamaguchi N, et al. 2020. eLife. 8:e52135.. PubMed
- Yu XX, et al. 2021. Cell Res. 31:886. PubMed
- Segal JM, et al. 2019. Nat Commun. 10:3350. PubMed
- Gao Q, et al. 2019. J Exp Med. 216:688. PubMed
- Puca L, et al. 2018. Nat Commun. 9:2404. PubMed
- Yamashiro C, et al. 2020. Nat Protoc. 15:1560. PubMed
- Apostolou P, Ntanovasilis D, and Papasotiriou I. 2017. J Biol Res (Thessalon). 10.1186/s40709-017-0068-9. PubMed
- Mota STS, et al. 2019. Int J Mol Sci. 20. PubMed
- Go YH, et al. 2022. Cancers (Basel). 14:. PubMed
- Shultz L, et al. 2010. Proc Natl Acad Sci U S A. 107:13022. PubMed
- Marquez-Curtis LA, et al. 2022. PLoS One. 17:e0263005. PubMed
- Jayasinghe MK, et al. 2022. Theranostics. 12:3288. PubMed
- Haraguchi T, et al. 2016. Sci Rep. 6:21117. PubMed
- Koh SB, et al. 2021. NPJ Precis Oncol. 5:85. PubMed
- Skrbo N, et al. 2014. PLoS One. 9:113278. PubMed
- Chua CW, et al. 2018. Elife. 7. PubMed
- Lo PK, et al. 2018. Elife. 7:e31334. PubMed
- Liu L, et al. 2018. Clin Cancer Res. 24:2370. PubMed
- Hornburg M, et al. 2021. Cancer Cell. . PubMed
- Yoshida K, et al. 2020. Nature. 578:266. PubMed
- Fujii M, et al. 2018. Cell Stem Cell. 23:787. PubMed
- Murase Y, et al. 2020. EMBO J. 39:e104929. PubMed
- Huerta–Nu? ez LFE, et al. 2019. Sci Rep. 9:6419. PubMed
- Chen D, et al. 2019. Cell Rep. 29:4568. PubMed
- Balakrishnan A, et al. 2019. Clin Cancer Res. 25:7506. PubMed
- Dhanwani R, et al. 2020. Sci Adv. 6:eaba3688. PubMed
- Hancock GV, et al. 2021. Stem Cell Res. 55:102493. PubMed
- Enge M, et al. 2017. Cell. 171:321. PubMed
- Mou H, et al. 2021. Cell Reports. 35(3):109011. PubMed
- Yamashiro C, et al. 2020. Nature Protocols. 362(6412):356-360. PubMed
- Grant RA, et al. 2021. Nature. 590(7847):635-641. PubMed
- Chen D et al. 2018. Cell reports. 25(13):3591-3602 . PubMed
- Nian Z, et al. 2021. Clin Cancer Res. 27:6026. PubMed
- Xiang X, et al. 2022. Nat Commun. 13:463. PubMed
- Mithal A, et al. 2020. Nat Commun. 0.607638889. PubMed
- Wosen JE, et al. 2019. Front Immunol. 1.784722222. PubMed
- Kojima Y et al. 2017. Cell stem cell. 21(4):517-532 . PubMed
- Chen D, et al. 2017. Biol Reprod. 97:850. PubMed
- Yan X, et al. 2019. Oncol Rep. 41:1938. PubMed
- Malenica I, et al. 2021. Nat Commun. 12:5209. PubMed
- Yuan W, et al. 2021. Int J Biol Sci. 17:527. PubMed
- Monterosso ME, et al. 2021. Sci Rep. 5118:11. PubMed
- Nelson L, et al. 2015. Sci Rep. 5: 17455. PubMed
- Menck K, et al. 2017. J Extracell Vesicles. 10.1080/20013078.2017.1340745. PubMed
- Zhang Y et al. 2018. Cell stem cell. 23(4):516-529 . PubMed
- Ludwig LS et al. 2019. Cell. 176(6):1325-1339 . PubMed
- RRID
- AB_756081 (BioLegend Cat. No. 324207) AB_756082 (BioLegend Cat. No. 324208)
- Structure
- Type I transmembrane protein, contains six disulfide bridges, one THYRO domain, approximate molecular weight 40 kD.
- Distribution
-
Highly expressed in bone marrow, colon, lung, and most normal epithelial cells. Also highly expressed on carcinomas of gastrointestinal origin. Expressed during early erythrogenesis.
- Function
- Homotypic calcium-independent cell adhesion. CD326 is believed to be involved in carcinogenesis by its ability to induce genes involved in cellular metabolism and proliferation.
- Modification
- Glycosylated.
- Cell Type
- Embryonic Stem Cells, Epithelial cells
- Biology Area
- Cell Biology, Immunology, Stem Cells
- Molecular Family
- Adhesion Molecules, CD Molecules
- Antigen References
-
1. Strnad J, et al. 1989. Cancer Res. 49:314.
2. Munz M, et al. 2004. Oncogene 23:5748.
3. Rao CG, et al. 2005. Int. J. Oncol. 27:49.
- Gene ID
- 4072 View all products for this Gene ID
- UniProt
- View information about CD326 on UniProt.org
